Timeline

Voting rights breakdown

Declared beneficial owners · 5

A single, collectively filed disclosure: the voting-rights rate applies to the whole group, not to each person.

• 1. Jan Schoch9.4%
• 2. Sandro Dorigo9.4%
• 3. Lukas Ruflin9.4%
• 4. Thabatseka LP9.4%
• 5. Clairmont Trust Company Limited9.4%

Notice details

Beneficial owner

1. Jan Schoch

Background: Group members 1 - 5 are subject to phased lock-up undertaking with Credit Suisse (acting on behalf of the managers in the IPO of Leonteq AG in October 2012) that commenced on 5 October 2012 and ends on 19 October 2017 in respect to the shares owned by them immediately before the IPO of Leonteq AG ("IPO Lock-up"). On 19 October 2015, one third of the shares subject to IPO Lock-up have been unlocked ("2015 Shares"); on 19 October 2016, the second third of the shares subject to IPO Lock-up have been unlocked ("2016 Shares") and on 19 October 2017, the last third of the shares subject to IPO Lock-up will be unlocked ("2017 Shares"). On 23 July 2015, Group member 1 and 4 have each entered into a new lock-up undertaking in favour of Raiffeisen Schweiz Genossenschaft, CH-9004 St. Gallen, with respect to their 2016 Shares and 2017 Shares (representing in aggregate 8.44% of the voting rights) that will commence on 19 October 2016 (with respect to their 2016 Shares, group member 1 representing 2.12% and group member 4 representing 2.10% of the voting rights) and on 19 October 2017 (with respect to their 2017 Shares, group member 1 representing 2.12% and group member 4 representing 2.10% of the voting rights) and will end in each case on 19 October 2020. On 23 November 2015 this Lock-up has been extended until 19 October 2025. Furthermore, Sandro Dorigo has moved his domicile to Singapore on 1 February 2016. Clairmont Trust Company Limited acts as trustee of a trust which holds through Thabatseka LP (which in turn is indirectly wholly owned by Clairmont Trust Company Limited) shares in Leonteq AG subject to lock-up undertaking. The trust was settled by Lukas Ruflin.